Phosphoric acid 4-formyl-5-hydroxy-6-methyl-pyridin-3-ylmethyl ester methyl ester | 26210-16-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Phosphoric acid 4-formyl-5-hydroxy-6-methyl-pyridin-3-ylmethyl ester methyl ester
• 英文别名: Phosphoric acid, mono((4-formyl-5-hydroxy-6-methyl-3-pyridinyl)methyl) monomethyl ester；(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl methyl hydrogen phosphate
• CAS: 26210-16-2
• 化学式: C₉H₁₂NO₆P
• 分子量: 261.171
• InChiKey: KFZLIGBUBKVOQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] PYRIDINE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS PYRIDINIQUES ET PROCÉDÉS D'UTILISATION
  申请人：LINK TECHNOLOGIES LTD

  公开号：WO2015132577A1

  公开（公告）日：2015-09-11

  The invention relates to compounds for use in the modification of compounds comprising nucleic acid sequences (such as oligonucleotides or the like), to modified oligonucleotides, to the delivery of modified oligonucleotides to cells and the like, and to the treatment of conditions by the delivery of modified oligonucleotides. The invention provides pyridine derived phosphoramidites, phosphorothioates, phosphate esters, solid supported equivalents, related oligonucleotides and the delivery of these to cells.

  该发明涉及用于修改包含核酸序列（如寡核苷酸等）的化合物的化合物，修改后的寡核苷酸，将修改后的寡核苷酸递送到细胞等，以及通过递送修改后的寡核苷酸来治疗疾病的方法。该发明提供了吡啶衍生磷酰胺酯、磷硫酸酯、磷酸酯、固相支持等价物、相关寡核苷酸以及将这些递送到细胞的方法。
• CROSSLINKING OF PROTEINS AND OTHER ENTITIES VIA CONJUGATES OF ALPHA-HALOACETOPHENONES, BENZYL HALIDES, QUINONES, AND THEIR DERIVATIVES
  申请人：Krantz Alexander

  公开号：US20130165382A1

  公开（公告）日：2013-06-27

  The present invention relates to the formation of conjugates (e.g., protein-protein dimers) using a-halo-acetophenones, benzylic halides, quinones, and related compounds as a conjugating system. The invention also features compositions that include the conjugates described herein, as well as uses of these conjugates in methods of medical treatment.
• PHARMACEUTICAL COMPOSITION FORMED BY COMBINING PYRIDOXAMINE COMPOUND AND THIAMINE COMPOUND
  申请人：RENASCIENCE CO., LTD.

  公开号：US20210000829A1

  公开（公告）日：2021-01-07

  Vitamin B1 deficiency caused when a pyridoxamine compound is administered in a large amount is prevented and/or treated. A pharmaceutical composition formed by combining at least one pyridoxamine compound selected from the group consisting of pyridoxamine and pharmaceutically acceptable salts thereof and at least one thiamine compound selected from the group consisting of thiamine, derivatives thereof, and pharmaceutically acceptable salts thereof, is administered.
• US9770515B2
  申请人：——

  公开号：US9770515B2

  公开（公告）日：2017-09-26